Genentech Overview

  • Year Founded
  • 1976

Year Founded

  • Status
  • Private

  • Employees
  • 20,343

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Latest Deal Amount
  • $46.8B

  • Investors
  • 1

Genentech General Information

Description

Developer of pharmaceutical products intended to serve people with serious and life-threatening diseases. The company offers pharmaceutical products that have applications in ophthalmology, metabolism and virology fields, including antibodies for cancer and medicine for primary progressive multiple sclerosis. thereby enabling patients to avail the treatment of life-threatening diseases to live healthier lives.

Contact Information

Website
www.gene.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Corporate Office
  • 1 DNA Way Mailstop 258A
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genentech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 12-Mar-2009 $46.8B 00.000 00000 Completed Generating Revenue
7. Secondary Transaction - Open Market 26-Oct-1999 00.000 Completed Generating Revenue
6. IPO 20-Jul-1999 00.000 00.000 000.00 Completed Generating Revenue
5. Corporate 17-Jun-1999 00.00 000.00 Completed Generating Revenue
4. Merger/Acquisition 03-Feb-1990 00.00 000.00 00.00 Completed Generating Revenue
3. IPO 14-Oct-1980 0000 000.00 Completed Generating Revenue
2. Early Stage VC 17-Oct-1979 $10M $10.2M Completed Generating Revenue
1. Early Stage VC 01-Jan-1976 $200K $200K Completed Generating Revenue
To view Genentech’s complete valuation and funding history, request access »

Genentech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical products intended to serve people with serious and life-threatening diseases. The company of
Biotechnology
South San Francisco, CA
20,343 As of 2024
00.000
00000 0000-00-00
00000000000 00.000

000000

t, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et do
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000.00 0000-00-00
000000&0 00.000

000000

a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
000000000000000
Ingelheim Am Rhein, Germany
00000 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genentech Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seagen Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
Boehringer Ingelheim Corporation Ingelheim Am Rhein, Germany 00000
Merck & Co. Corporation Rahway, NJ 00000 0000 000000000 - 0000
Idorsia Pharmaceuticals Corporate Backed or Acquired Allschwil, Switzerland 000 00.000 00000000 00.000
Alexion Formerly VC-backed Boston, MA 0000 00.000 000000&0 00.000
You’re viewing 5 of 33 competitors. Get the full list »

Genentech Patents

Genentech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-202024000928-U1 Omalizumab injection Active 10-May-2024 000000000 0
US-12030959-B1 Anti-ige antibody therapy for multiple food allergies Active 05-Jul-2023 00000000000 00
US-20240202920-A1 Spatial analysis of mitotic figures in histopathological images Pending 16-Dec-2022 0000000000
US-20240189774-A1 Real-time automated monitoring and control of ultrafiltration/diafiltration (uf/df) conditioning and dilution processes Pending 12-Dec-2022 000000000
US-20240228512-A1 Acyclic oxazepine compounds comprising a 6-aza moiety and uses thereof Pending 19-Oct-2022 C07D519/00
To view Genentech’s complete patent history, request access »

Genentech Executive Team (51)

Name Title Board Seat Contact Info
Ashley Magargee Chief Executive Officer & Head of Commercial Portfolio
Ed Harrington Chief Financial Officer
Jayson Johnson Head of D&I Business Partnering and Learning & Development
Parminder Kahlon Principal & Programmer AnalystPrincipal
Joel Vidal-Phillips Principal
You’re viewing 5 of 51 executive team members. Get the full list »

Genentech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genentech Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Roche Corporation Majority 000 0000 000000 0
To view Genentech’s complete investors history, request access »

Genentech Investments & Acquisitions (37)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Herophilus (Orchard, Orchestra, and OrCA technologies) 07-Sep-2023 000000000 Drug Discovery
HealthMyne (Healthcare Assets) 30-Jun-2022 000000000 00.00 Buildings and Property
Prescient Design 01-Aug-2021 0000000000 Biotechnology
Atalanta Therapeutics 11-Jan-2021 00000 0000 00000 Drug Discovery
MVT 11-Sep-2019 Merger/Acquisition Diagnostic Equipment
You’re viewing 5 of 37 investments and acquisitions. Get the full list »

Genentech Subsidiaries (2)

Company Name Industry Location Founded
Seragon Drug Discovery Irvine, CA 2013
Genentech (Biologics Manufacturing Unit) Biotechnology Vacaville, CA
To view Genentech’s complete subsidiaries history, request access »

Genentech Exits (21)

Company Name Exit Date Exit Type Exit Size Status Buyers
Immunocore 16-Jul-2015 00000 00000 00 00000 Completed
  • 11 buyers
Constellation Pharmaceuticals 05-Aug-2014 00000 00000 00 000 Completed
  • 5 buyers
Immunogen 20-Sep-2013 0000 000.00 Completed
  • 000000000
Constellation Pharmaceuticals 01-Jan-2012 00000 00000 00 0000 Completed
  • 000000000
Symphogen 04-Feb-2009 Later Stage VC 000.00 Completed
  • 5 buyers
You’re viewing 5 of 21 exits. Get the full list »

Genentech FAQs

  • When was Genentech founded?

    Genentech was founded in 1976.

  • Who is the founder of Genentech?

    Robert Swanson and Herbert Boyer Ph.D are the founders of Genentech.

  • Who is the CEO of Genentech?

    Ashley Magargee is the CEO of Genentech.

  • Where is Genentech headquartered?

    Genentech is headquartered in South San Francisco, CA.

  • What is the size of Genentech?

    Genentech has 20,343 total employees.

  • What industry is Genentech in?

    Genentech’s primary industry is Biotechnology.

  • Is Genentech a private or public company?

    Genentech is a Private company.

  • What is the current valuation of Genentech?

    The current valuation of Genentech is 00000.

  • What is Genentech’s current revenue?

    The current revenue for Genentech is 00000.

  • How much funding has Genentech raised over time?

    Genentech has raised $1.94B.

  • Who are Genentech’s investors?

    Roche has invested in Genentech.

  • Who are Genentech’s competitors?

    Seagen, Boehringer Ingelheim, Merck & Co., Idorsia Pharmaceuticals, and Alexion are some of the 33 competitors of Genentech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »